November 07, 2023
1 min watch
Save
VIDEO: Perioperative pembrolizumab regimen seems ‘practice changing’ for early-stage NSCLC
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
MADRID — In this video, Julia Rotow, MD, highlighted positive OS data from the KEYNOTE-671 study of a perioperative pembrolizumab regimen for early-stage non-small-cell lung cancer presented at ESMO Congress.
“I firmly expect this to be a practice-changing option for our patients when I return to clinic,” Rotow, clinical director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, said of the pembrolizumab (Keytruda, Merck) regimen.
Reference:
- Spicer JD, et al. Abstract LBA56. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Rotow reports numerous ties to industry.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.